Filing summary
Entity and period: The supplied filing is FibroGen, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2023, not a filing for Kyntra Bio, Inc. FibroGen is a biopharmaceutical company with commercial roxadustat sales in China and a pipeline led by Phase 3 candidate pamrevlumab.
Financial performance and position
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Total revenue | $36.2 million | $60.8 million; down 41% |
| Operating costs and expenses | $112.3 million | $123.8 million; down 9% |
| Loss from operations | $76.1 million | $63.0 million |
| Net loss | $76.7 million | $63.2 million |
| Net loss per share | $0.81 | $0.68 |
| Net cash used in operations | $101.6 million | $8.5 million |
Revenue comprised $24.2 million net product revenue, $6.0 million license revenue, $3.9 million development and other revenue, and $2.1 million drug product revenue. China product revenue increased 28%, largely from higher sales to Falikang. The prior-year quarter included a $25.0 million Russian regulatory milestone under the Astellas agreement; its absence, along with lower collaboration development billings and drug product revenue, drove the overall revenue decline. No gross margin was stated in the supplied filing text.
At March 31, cash and cash equivalents were $188.6 million and short-term investments were $167.4 million; accounts receivable was $17.7 million. Together, cash, investments, and receivables totaled $373.6 million, down $69.1 million from year-end. Current assets were $430.5 million versus current liabilities of $254.7 million. Total liabilities were $567.4 million and total deficit was $28.9 million. Cash from operations was substantially affected by working-capital movements, including a $66.3 million decrease in accrued and other liabilities; investment maturities contributed $103.5 million of investing cash flow.
FibroGen raised approximately $31.1 million net through its at-the-market equity program, selling 1.54 million shares. At quarter-end, the company had a $51.6 million liability related to the sale of future Astellas revenues; the agreement has an estimated effective annual interest rate of 19.64%. The filing also reports $86.8 million in operating lease liabilities and $51.9 million in non-cancelable purchase obligations.
Material changes, outlook, and key risks
- Clinical programs: Management expected topline results in 2023 from pamrevlumab Phase 3 studies in non-ambulatory Duchenne muscular dystrophy and idiopathic pulmonary fibrosis, and from a roxadustat chemotherapy-induced anemia study in China. Results for ambulatory DMD were expected in Q3 2023. Additional pivotal readouts were expected in 2024.
- Trial setback: The Phase 3 arm of the MATTERHORN roxadustat study in myelodysplastic syndromes did not meet its primary endpoint. Transfusion independence was 47.5% for roxadustat versus 33.3% for placebo (p=0.217). Preliminary safety was described as generally consistent with prior findings; further safety evaluation was pending.
- Funding outlook: Management stated existing cash, investments, receivables, and expected resources were expected to support anticipated cash requirements for at least 12 months from the financial statements’ issuance. It also anticipated continuing losses and substantial additional funding needs thereafter. Cash-flow forecasts and funding adequacy remain subject to risks and uncertainty.
- Subsequent secured financing: On April 29, 2023, FibroGen entered into a loan agreement for a $75 million initial term loan, a $37.5 million milestone-dependent delayed draw, and a further uncommitted draw of up to $37.5 million at lenders’ discretion. Loans carry 14% annual interest, mature May 8, 2026, and are secured by substantially all company and guarantor assets, subject to exceptions. The agreement requires at least $30 million of unrestricted U.S. cash and includes restrictive covenants and default provisions.
- Other subsequent development: In May 2023, FibroGen licensed FOR46 under a four-year option to acquire Fortis Therapeutics, committing $5 million during the option period. Exercising the option would require $80 million plus potential contingent payments of up to $200 million.
- Additional risks and contingencies: The filing describes securities class-action and shareholder derivative litigation, an ongoing SEC investigation concerning roxadustat cardiovascular safety data, and challenges to certain roxadustat patents in China. No material legal accrual was recorded; outcomes and potential exposure could not be estimated. Other key risks include clinical and regulatory uncertainty, reliance on Astellas and AstraZeneca, China operations and cash-transfer restrictions, and ongoing financing needs.
Most important facts for investors to verify
- Confirm the issuer: the source filing is for FibroGen, Inc. (Nasdaq: FGEN), despite the request metadata naming Kyntra Bio, Inc.
- Check subsequent clinical readouts and regulatory developments, particularly the pamrevlumab Phase 3 results and the MATTERHORN setback.
- Review actual cash burn and working-capital trends; Q1 operating cash use was $101.6 million, compared with $8.5 million a year earlier.
- Confirm funding received and conditions on the post-quarter secured loans, including the $30 million U.S. minimum-cash covenant and 14% interest rate.
- Assess China roxadustat sales, pricing and reimbursement after the stated reimbursement period, and the company’s ability to access or transfer China-held funds.
- Track the Astellas revenue-interest obligations, collaboration funding and potential legal or regulatory liabilities.